Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Abstract Introduction Lebrikizumab is a novel monoclonal antibody with established efficacy in patients with moderate-to-severe atopic dermatitis (AD) in multiple Phase 3 trials. One of the ultimate treatment goals for patients with moderate-to-severe AD is to achieve stable disease control without...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline Pierce, Helena Agell, Sonja Ständer
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2024-08-01
Col·lecció:	Dermatology and Therapy
Matèries:	Atopic dermatitis Eczema Fluctuations Lebrikizumab Response Stability
Accés en línia:	https://doi.org/10.1007/s13555-024-01226-9
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!